Evidence map›Paper›PMID 41777897›Full record

ReviewFrontiers in immunology2026

Research on microbial communities in tumor microenvironments: cutting-edge dynamics and future trends from a bibliometric perspective.

Xuan Tang, Changfeng Man, Ziyan Liu, Dandan Gong, Yu Fan

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xuan TangCancer Institute, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Changfeng ManCancer Institute, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Ziyan LiuCancer Institute, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Dandan GongCancer Institute, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Yu FanCancer Institute, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In recent years, researchers have identified numerous potential biomarkers and therapeutic targets applicable to cancer immunotherapy, among which the role of tumor-internal microorganisms in the tumor microenvironment has been explored. However, this field is still in its early stages of development, facing limitations such as the unclear mechanisms of interaction between tumor-internal microorganisms and host immunity, as well as significant variations in microbial profiles among different tumor types and patients. Objective: This study aims to explore the research hotspots and development trends of tumor-internal microorganisms through bibliometric methods and to construct a systematic knowledge map. Methods: This study retrieved publications related to tumor-internal microorganisms from the Web of Science Core Collection (WOSCC) prior to December 22, 2025. Subsequently, the selected literature was analyzed using VOSviewer (v.1.6.20), CiteSpace (v.6.4.1R), and SCImago Graphica. In addition, we integrated PubMed data to assess status and trends in preclinical and clinical studies of intratumoral microbiota interventions for anti-tumor therapy efficacy. Results: From the Web of Science database, we retrieved 1,278 relevant articles. Since 2012, the number of papers published on the intratumoral microbiota has shown an overall upward trend. China and the United States are the two major countries in this field. Keyword analysis shows that "tumor microbiome," "gut microbiome," "cancer," and "

Indexed as

MicrobiotaNeoplasmsTumor MicroenvironmentAnimalsBibliometricsHumansImmunotherapybibliometric analysiscancer therapyFusobacterium nucleatumimmune microenvironmentintratumoral microbiota

Identifiers

PMID41777897
PMCPMC12950562

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.